Cerchione, Claudio

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Ribas de Almeida, A. C., Hajek, R., Kim, K., Grosicki, S., et al. (2024) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 199

Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial

Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Hájek, R., Kim, K., Grosicki, S., Sia, H., et al. (2025) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 35

Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon

Martino, M., Naso, V., Loteta, B., Canale, F. A., Pugliese, M., Alati, C., Musuraca, G., Nappi, D., Gaimari, A., Nicolini, F., et al. (2022) · International Journal of Molecular Sciences

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 17

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

Bruzzese, A., Derudas, D., Galli, M., Martino, E. A., Rocco, S., Conticello, C., Califano, C., Giuliani, N., Mangiacavalli, S., Farina, G., et al. (2022) · Hematological Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 17

Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis

Cerchione, C., Peluso, I., Nappi, D., Pareto, A. E., Picardi, M., Martinelli, V., & Pane, F. (2017) · Annals of Hematology

Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 12